{"id":"menadoxime","rwe":[],"tags":[{"label":"menadoxime","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"kapilon","offLabel":[],"synonyms":["kapilon","menadoxime"],"timeline":[],"approvals":[],"brandName":"Kapilon","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"menadoxime","explanation":"Think of acetylcholine like a key that unlocks muscles to make them move. When acetylcholine is broken down too quickly, it can't do its job properly. Kapilon helps by slowing down the breakdown of acetylcholine, so it can keep unlocking muscles and helping them function.","oneSentence":"Kapilon works by inhibiting the enzyme acetylcholinesterase, which breaks down the neurotransmitter acetylcholine.","technicalDetail":"Kapilon acts as a reversible inhibitor of acetylcholinesterase, the enzyme responsible for hydrolyzing acetylcholine into choline and acetic acid, thereby increasing acetylcholine levels in the synaptic cleft and enhancing cholinergic transmission."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3337","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=menadoxime","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:34:17.017844","biosimilars":[],"competitors":[],"genericName":"menadoxime","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"0UQZ6GMA89","CHEBI":"CHEBI:134997","UMLSCUI":"C2983981","ChEMBL_ID":"CHEMBL2110691","PUBCHEM_CID":"73656839"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Kapilon, also known as menadoxime, is a small molecule drug in the menadoxime class. Its exact target and mechanism of action are unknown, but it is believed to work by inhibiting acetylcholinesterase, an enzyme that breaks down acetylcholine, a neurotransmitter involved in muscle contraction and other functions. Kapilon's commercial status and approved indications are unclear, and it is not known whether it is patented or available as a generic medication. Further research is needed to fully understand Kapilon's properties and potential uses. As a result, key safety considerations and pharmacokinetic parameters, such as half-life and bioavailability, are also unknown.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}